Document is current
Any future updates will be listed below
-
Authors
Leiby, Katherine L. https://orcid.org/0000-0003-3409-9371
Yuan, Yifan
Ng, Ronald
Raredon, Micha Sam Brickman https://orcid.org/0000-0003-1441-6122
Adams, Taylor S. https://orcid.org/0000-0003-4280-9070
Baevova, Pavlina https://orcid.org/0000-0002-0817-0261
Greaney, Allison M. https://orcid.org/0000-0002-6316-0410
Hirschi, Karen K.
Campbell, Stuart G.
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
Herzog, Erica L.
Niklason, Laura E. https://orcid.org/0000-0002-5156-504X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01HL145567, R01HL138540, F30HL143880, T32GM136651, F30HL143906, T32GM136651, HL146056, EB017103, R01HL127349, R01HL141852, UH2HL123886, U01HL145567, R01HL152677)
U.S. Department of Health & Human Services | National Institutes of Health
Unrestricted research gift from Humacyte Inc.
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
American Heart Association (20POST35210709)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
National Science Foundation (1653160)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
A generous gift from Three Lakes Partners
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 19 October 2022
Accepted: 6 April 2023
First Online: 28 April 2023
Competing interests
: The authors declare the following competing interests: L.E.N. is the CEO, founder and shareholder in Humacyte, Inc, which is a regenerative medicine company. Humacyte produces engineered blood vessels from allogeneic smooth muscle cells for vascular surgery. L.E.N.’s spouse has equity in Humacyte, and L.E.N. serves on Humacyte’s Board of Directors. L.E.N. is an inventor on patents that are licensed to Humacyte and that produce royalties for L.E.N. L.E.N. has received an unrestricted research gift to support research in her laboratory at Yale. Humacyte did not influence the conduct, description or interpretation of the findings in this report. N.K. served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira, Astra Zeneca, RohBar, Veracyte, Augmanity, CSL Behring, Galapagos and Thyron over the last 3 years, reports Equity in Pliant and Thyron, and grants from Veracyte, Boehringer Ingelheim, BMS and non-financial support from MiRagen and Astra Zeneca. N.K. has IP on novel biomarkers and therapeutics in IPF licensed to Biotech. The remaining authors declare no competing interests.
